Table 1 Clinical information on the patients included in the study
From: The dynamic immune behavior of primary and metastatic ovarian carcinoma
Location | Patient ID | Treatment status | Stage | Age, years |
|---|---|---|---|---|
Primary | Pt1 | Untreated | IIIC | 46 |
Pt2 | Untreated | IIIA1 | 73 | |
Pt3 | Untreated | IIIA1ii | 49 | |
Pt4 | Untreated | IIIB | 75 | |
Pt5 | Post NACT | IIIC | 76 | |
Pt6 | Untreated | IIIB | 56 | |
Pt7 | Untreated | IIIC | 58 | |
Pt8 | Untreated | IIB | 33 | |
Pt9 | Untreated | IIB | 70 | |
Pt10 | Untreated | IIIB | 52 | |
Pt11 | Post NACT | IIIB | 44 | |
Pt12 | Untreated | IIIA1 | 65 | |
Pt13 | Untreated | IIB | 66 | |
Pt14 | Post NACT | IVB | 56 | |
Omentum | Pt15 | Post NACT | IIIB | 67 |
Pt16 | Post NACT | IIIC | 67 | |
Pt17 | Post NACT | IIIC | 65 | |
Pt18 | Untreated | IIIB | 60 | |
Pt19 | Untreated | IIIC | 74 | |
Normal (ovary) | Normal | Untreated | 56 |
